LKFT
Lakefront Biotherapeutics N.V.
LKFT's fundamentals are strong: revenue more than tripled and its operating margin went from −127% to 62%, though free cash flow turned negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LKFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
LKFT's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
LKFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.2x | $32.15 | -5.2% |
| Current | 3.4x | $33.93 | — |
| Fair | 3.5x | $35.61 | +5% |
| Expensive | 5.1x | $51.37 | +51% |
Historical ranges are pointers, not guarantees.
LKFT's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.
LKFT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LKFT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LKFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$0.67 | +$0.54 |
| Q3 2023 | -$0.72 | -820% |
| Q2 2023 | -$0.79 | +$0.58 |
LKFT has returned to profit: it earned $10.05 per share over the past year, after losing money the year before.
LKFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.5M | -81% |
| Q1 2026 | $7.2M | -91% |
| Q4 2025 | $1B | +1093% |
| Q3 2025 | $79.1M | +19% |
| Q2 2025 | $72.5M | -16% |
| Q1 2025 | $83.3M | +20% |
| Q3 2024 | $66.5M | -50% |
| Q2 2024 | $86.5M | +30% |
LKFT's revenue is growing: $13M last quarter, down 81% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -359% | -272 points |
| Q1 2026 | -983% | -771 points |
| Q4 2025 | 84% | +192 points |
| Q3 2025 | -59% | +32 points |
| Q2 2025 | -87% | -38 points |
| Q1 2025 | -212% | -159 points |
| Q4 2024 | -107% | N/A |
| Q3 2024 | -91% | -66 points |
LKFT's operating margin was −359% last quarter, down 272 points from the same quarter a year ago, near the bottom of its range since 2017.
LKFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$125.5M |
| Q4 2020 | -$278.6M | -108% |
| Q4 2019 | $3.7B | +$3.8B |
| Q4 2018 | -$65.1M | +$104.2M |
LKFT has burned cash in most quarters: −$219M over the past year, against $3.2B the year before.
LKFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
LKFT has more cash than debt.
LKFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 87.8 | Overbought |
LKFT's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
LKFT PE vs Healthcare Sector
| Metric | LKFT | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
| PE % | 39 | 29 | 10 pts above |
LKFT is trading at 3.4x earnings, a 87% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LKFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 8.7% above |
| 20 week MA | $29.6 | 15% above |
| 50 week MA | $30.4 | 12% above |
| 100 week MA | $29.6 | 15% above |
| 200 week MA | $32.2 | 5.5% above |
LKFT has climbed back above all five of its weekly moving averages, and it's now 5.5% above its 200-week average.
LKFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.4 | $99.3 | -53% |
| 2021 | $99.3 | $55.9 | -44% |
| 2022 | $55.9 | $42.2 | -25% |
| 2023 | $42.2 | $40.7 | -3.7% |
| 2024 | $40.7 | $27.3 | -33% |
| 2025 | $27.3 | $33.0 | +21% |
| 2026 YTD | $33.0 | $33.9 | +2.7% |
LKFT has finished lower in five of the last six years. It's up 2.7% so far in 2026.